Financial Disclosure: Dr Kuntsi has received a speaker's fee from Eli Lilly and Company that has been used for educational and research activities. Dr Buitelaar has in the past 3 years been a consultant to, member of advisory boards of, and/or speaker for Bioprojet, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag BV, Medice, Organon/Shering Plough, Pfizer, Shire, UCB Pharma, and Servier. Dr Sergeant is a member of an advisory board to Eli Lilly and Company and Shire and has received research funding from Eli Lilly and Company; educational grants from Eli Lilly and Company, Janssen-Cilag, and Shire; and speaker's fees from Eli Lilly and Company, Janssen-Cilag, and Shire. Dr Sonuga-Barke is a member of advisory boards to Astra Zeneca, Flynn Pharma, Shire, and UCB Pharma; has received research support from Janssen-Cilag, Qbtech, and Shire and conference support from Shire; is on a speakers' board for Shire and UCB Pharma; and has been a consultant for Shire and UCB Pharma. Dr Uebel received conference attendance support or was paid for public speaking by Eli Lilly and Company, Janssen-Cilag, and Medice and received research support from Schwabe and Shire. Dr Miranda is an advisor to Eli Lilly and Company. Dr Oades has received support for investigator-initiated studies from UCB GmbH. Dr Roeyers is a member of an advisory board to Shire and has received research funding and conference attendance support from Eli Lilly and Company. Dr Rothenberger is on the advisory board and speakers' bureau of Eli Lilly and Company, Medice, Novartis, and Shire; has received educational grants from Medice and Shire; and has received research support from Schwabe and Shire. Dr Steinhausen has served as an advisor and speaker to Eli Lilly and Company, Janssen-Cilag, Novartis, Shire, and UCB Pharma. In the past year, Dr Faraone has received consulting fees and has been on advisory boards for Eli Lilly and Company, Ortho-McNeil, and Shire and has received research support from Eli Lilly and Company, Pfizer, Shire, and the National Institutes of Health (NIH). In previous years, Dr Faraone has received consulting fees, been on advisory boards, or been a speaker for Eli Lilly and Company, Janssen, McNeil, Novartis, Pfizer, and Shire and has received research support from Eli Lilly and Company, Pfizer, Shire, and the NIH. Dr Asherson has received funding for educational and research activities from Janssen-Cilag and Shire and has received consultancy and speaker fees from Eli Lilly and Company, Flynn Pharma, Janssen-Cilag, and Shire that have been used for educational and research activities.